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Abstract
Background: National newborn screening programmes based on tandem-mass spectrometry (MS/MS) and other
newborn screening (NBS) technologies show a substantial variation in number and types of disorders included in
the screening panel. Once established, these methods offer the opportunity to extend newborn screening panels
without significant investment and cost. However, systematic evaluations of newborn screening programmes are
rare, most often only describing parts of the whole process from taking blood samples to long-term evaluation of
outcome.
Methods: In a prospective single screening centre observational study 373 cases with confirmed diagnosis of a
metabolic disorder from a total cohort of 1,084,195 neonates screened in one newborn screening laboratory
between January 1, 1999, and June 30, 2009 and subsequently treated and monitored in five specialised centres
for inborn errors of metabolism were examined. Process times for taking screening samples, obtaining results,
initiating diagnostic confirmation and starting treatment as well as the outcome variables metabolic
decompensations, clinical status, and intellectual development at a mean age of 3.3 years were evaluated.
Results: Optimal outcome is achieved especially for the large subgroup of patients with medium-chain acyl-CoA
dehydrogenase deficiency. Kaplan-Meier-analysis revealed disorder related patterns of decompensation. Urea cycle
disorders, organic acid disorders, and amino acid disorders show an early high and continuous risk, medium-chain
acyl-CoA dehydrogenase deficiency a continuous but much lower risk for decompensation, other fatty acid
oxidation disorders an intermediate risk increasing towards the end of the first year. Clinical symptoms seem
inevitable in a small subgroup of patients with very early disease onset. Later decompensation can not be
completely prevented despite pre-symptomatic start of treatment. Metabolic decompensation does not necessarily
result in impairment of intellectual development, but there is a definite association between the two.
Conclusions: Physical and cognitive outcome in patients with presymptomatic diagnosis of metabolic disorders
included in the current German screening panel is equally good as in phenylketonuria, used as a gold standard for
NBS. Extended NBS entails many different interrelated variables which need to be carefully evaluated and
optimized. More reports from different parts of the world are needed to allow a comprehensive assessment of the
likely benefits, harms and costs in different populations.
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The advent of tandem mass spectrometry (MS/MS)
allowed for a substantial increase in the number of disor-
ders included in the newborn screening (NBS) panel [1].
At present national NBS programmes differ widely. The
American College of Clinical Genetics proposed 29 core
and 25 secondary conditions [2], the German panel
includes 12 metabolic disorders [3], the United Kingdom
(UK) screens for phenylketonuria and medium-chain acyl-
CoA dehydrogenase deficiency [4], France for phenylketo-
nuria only [5], and Hongkong for no metabolic disorder
but hypothyroidism [6]. Recommendations for the screen-
ing process also vary, e.g. for time of blood sampling
between 24 hours (USA), 48 to 72 hours (Germany) to
120 hours (UK). Laboratory cut-offs and algorithms for
confirmatory diagnostics are also not standardised.
Although the criteria proposed by Wilson and Jungner
in 1968 [7] for NBS programmes are still accepted [2],
they have been modified mainly driven by new technolo-
gies but without systematic evaluation of treatment and
outcome yet [8]. Programme effectiveness, quality assur-
ance and programme evaluation have been suggested as
amendments to the Wilson and Jungner criteria [9,10].
Patients and methods
Panel of screened disorders
During a pilot period from January 1999 until April
2005 the panel of disorders was not officially regulated
in Germany, and all disorders recommended in the US
panel were screened for in our centre (N = 583,553 neo-
nates). In December 2004 the regulatory authority for
NBS was transferred to a national commission resulting
in an officially implemented panel of 12 defined meta-
bolic disorders to be exclusively screened from May
2005 onwards (N = 500,642 neonates) (Table 1 super-
script a)[3]. At the same time written informed consent
became mandatory. The recommended time for blood
sampling was between day of life three to five before
2002 and between 36 and 72 hours thereafter [11].
Population
Between January 1, 1999 and June 30, 2009, the NBS
centre of the University of Heidelberg analysed dried
blood spots of 1,084,195 neonates from three South-
Western German states. Ninety percent of NBS samples
were sent from obstetric units or children’s hospitals
and 10% from midwives or general paediatricians. MS/
MS NBS was performed as described previously in a
preliminary report from our centre [12].
Cases with confirmed diagnosis of a metabolic disorder
In 377 cases confirmatory diagnostics was recommended.
A metabolic disorder was confirmed in 373 cases. Mini-
mal criteria for accepting a diagnosis as confirmed are
stated in Table 1. In four cases a disorder was suspected,
but further confirmatory investigation was not possible
due to early death (one suspicion of tyrosinaemia type I,
one of medium-chain acyl-CoA dehydrogenase defi-
ciency) or because cases were lost to follow-up (one sus-
picion of methylmalonic aciduria, one of carnitine
transporter deficiency) (Table 1). Maternal 3-methylcro-
tonyl-CoA carboxylase deficiency was diagnosed in 6 of
the 373 cases. To our knowledge there has been no false
negative screening result. Positive screens were commu-
nicated by phone as well as by fax and/or mail for all
samples but for hyperphenylalaninaemias, where a sec-
ond sample was only requested by fax and/or mail. The
study sample was subdivided into three groups: Group 1
(NBS) comprised 355 neonates with a high suspicion of a
metabolic disorder resulting from regular NBS, group 2
(symptomatic) contained 11 patients diagnosed because
of clinical symptoms before NBS blood sample was taken
or before NBS result was available. In group 3 (high risk,
11 patients) specific metabolic analyses were performed
immediately after birth (n = 10) or even prenatally (n =
1) due to a known family risk. Eighty percent of neonates
screened positive were further investigated in seven spe-
cialised metabolic units versus 20% in local Paediatric
departments.
Process evaluation
377 data sets could be analysed for process times and
process durations (Table 1). The screening process was
analysed in five sequential steps from blood sampling
(step 1), report of first screening result (step 2), start of
confirmatory testing (step 3), confirmation of result
(step 4), and start of treatment (step 5). Process times
were calculated as the child’s age at a particular step
(days/hours for steps 1 and 2; days for steps 3 to 5) and
‘process duration’ as the time difference between steps.
‘Start of confirmation’ was defined as the start of speci-
fic investigations, except for mild hyperphenylalaninae-
mia, for which start of confirmation was defined as the
time of the first repeat specimen.
Outcome evaluation
The target sample for outcome evaluation included 257
cases in group 1 (excluding 88 babies with mild hyper-
phenylalaninaemia, six babies of mothers with maternal
3-methylcrotonyl-CoA carboxylase deficiency, four non-
definitely confirmed cases), 11 patients in group 2, and
11 patients in group 3. Ten patients were soon lost to
follow-up (one carnitine palmitoyltransferase II deficiency,
two medium-chain acyl-CoA dehydrogenase deficiency,
three short-chain acyl-CoA dehydrogenase deficiency,
one biotinidase deficiency, one galactosaemia, two
phenylketonuria), one patient with mitochondrial tri-
functional protein deficiency deceased at the age of six
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Page 2 of 10Table 1 Patient sample, diagnostic criteria and treatment modalities
Disorder N Group
1
NBS
Group 2
symptomatic
Group
3
high
risk
Treatment Confirmation of diagnosis
Minimal criteria to accept diagnosis as confirmed
Yes No Un-
known
Amino acid disorders/ Urea cycle disorders
PKU
a,f 85 84 1
b 79 0 6 Blood phenylalanine ≥ 600 μmol/L, normal urinary pterins and DBS
dihydropteridine reductase activity
MHP
a,f 88 88 2 61 25 First and control phenylalanine levels < 600 μmol/L, phenylalanine/
tyrosine < 3, normal urinary pterins and DBS dihydropteridine reductase
activity
PTPSD
e 1 1 1 Characteristic pterin profile in urine
MSUD
a, e 7 4 1 2 7 Elevated branched-chain amino acids including alloisoleucine
TYR I
e 2 2 2 Elevated succinylacetone in urine
TYR III
f 1 1 1 Tyrosine persistently > 500 μM, succinylacetone in urine normal, no
clinical indication for tyrosinaemia type II or liver dysfunction
Homocystinuria
f 0 Characteristic profile of homocysteine, methionine, cysteine in plasma
NKH
c,f 1 1 1 Elevated glycine in plasma and CSF and pathological ratio plasma/CSF
glycine
CIT I classic
e 4 1 3 3 1 Characteristic amino acid profile in plasma and ammonia in blood
CIT I mild
f 6 6 1 5 Characteristic amino acid profile in plasma and ammonia in blood,
molecular genetic analysis
ASLD
e 1 1 1 Characteristic amino acid profile in plasma and urine
Arginase
deficiency
f
0 Enzyme deficiency in erythrocytes
Fatty acid oxidation disorders
CPT ID
a,e 1 1 1 Enzyme deficiency in fibroblasts
CPT IID
a,e 1 1 1 Enzyme deficiency in fibroblasts
CACTD
a,e 0 Enzyme deficiency in fibroblasts
CTD
e 3 3 3 Pathological tubular carnitine reabsorption, fibroblast transport studies
MCADD
a,e 81 77 2 2 70 1 10 Characteristic acylcarnitine profile in plasma/DBS and/or
hexanoylglycine in urine and/or informative genotype
LCHADD/
mTFP
a,c,e
6 5 1 5 1 Characteristic acylcarnitine profile in plasma/DBS and/or informative
genotype and/or enzyme activity
VLCADD
a,e 6 6 6 Characteristic acylcarnitine profile in plasma/DBS and/or enzyme activity
in lymphocytes or fibroblasts and/or informative genotype
SCADD
f 9 9 3 6 Characteristic acylcarnitine profile in plasma/DBS and ethylmalonic acid
in urine and enzyme activity
MADD
e 3 3 2 1 Characteristic profiles of acylcarnitines in plasma and organic acids in
urine
Organic acid disorders
GA I
a,e 6 6 6 Characteristic urinary organic acid profile, informative genotype
IVA classic
a,e 5 4 1 5 Characteristic urinary organic acid profile
IVA mild
a,f 10 9 1 10 Characteristic urinary organic acid profile, informative genotype
MBD
f 0 Characteristic urinary organic acid profile
MMA/Cbl
e 4 3 1 4 Characteristic urinary organic acid profile +/- abnormal concentrations
of plasma homocysteine and methionine (complementation studies in
fibroblasts in all patients)
PA
e 4 3 1 4 Characteristic urinary organic acid profile
3-MCCD
f 8 8 5 2 1 Characteristic urinary organic acid profile
MHBD
e 0 Characteristic urinary organic acid profile, informative genotype
MGA
e 0 Characteristic urinary organic acid profile, informative genotype
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the neonatal period, four were too young for outcome
evaluation (≤1 year) and parents of 16 newborns did
not give consent. Therefore 247 patients were eligible
for outcome evaluation. Following a standardised pro-
tocol, paediatric metabolic specialists and psychologists
evaluated the clinical outcome by the number of meta-
bolic decompensations, dysfunction of selected organs,
growth disturbances, standardised IQ tests (1.5 yrs
Denver test, 3.5 yrs K-ABC or HAWIVA-III, 5.5 yrs
HAWIK-IV) as well as school placement. Metabolic
decompensation was defined as any event resulting in
hospitalization after a patient showed biochemical
markers of metabolic ‘derangement’ or clinical signs of
deterioration.
Data management and statistics
Screening data were taken from the database of the NBS
centre. Confirmatory diagnostics and outcome data were
retrieved from patients’ files. All data were entered in
standardised forms by the authors (GG, ML, PB, UW),
transferred to the study’s data base by a data manager
(Microsoft Access 2003), checked for consistency and
correctness and analyzed with SPSS Version 16.
Results
Part 1: Process analysis
Data sets including all five process steps were available
for 205 confirmed cases. Median ages (interquartile
ranges) were 2.9 days (2.34-4.00) for blood sampling
(step 1), 7.1 days (5.7-9.2) for the first report of the
screening result (step 2), 9.0 days (7.0-12.0) for start of
confirmatory testing (step 3), 11.0 days (8.0-15.0) for con-
firmation of result (step 4), and 10.0 days (7.0-13.0) for
start of treatment (step 5). 75% of all screening processes
from steps 1 to 5 were completed within the first 13 days
of life. Process times for mild hyperphenylalaninaemia vs.
other cases revealed similar times for step 1 (c
2(1, N =
345) = 1.55; p = 0.213), but longer times for step 2 (c
2(1,
N = 338) = 7.49; p < 0.01), step 3 (c
2(1, N = 336) = 13.05;
p < 0.001), and step 4 (c
2(1, N = 334) = 44.45; p < 0.001)
reflecting that for mild hyperphenylalaninaemia requests
for repeat specimen were sent out by mail/fax and not
communicated by phone. Median duration between steps
1 and 2 in patients who were screened according to the
official German regulation (after 2005) between 36 and
72 hrs was 3.32 days.
Bonferroni adjusted Kruskal-Wallis 2-tailed tests of dif-
ferences between group 1 (NBS), group 2 (symptomatic),
Table 1 Patient sample, diagnostic criteria and treatment modalities (Continued)
HCSD
e 0 Characteristic urinary organic acid profile, enzyme deficiency
BIOD
a,e 9 9 7 2 Enzyme deficiency in DBS and/or serum
KTD
e 0 Characteristic profiles of acylcarnitines in plasma and organic acids in
urine
HMG-CoA LD
e 1 1 1 Characteristic profiles of acylcarnitines in plasma and organic acids in
urine
Other
disorders
Galactosaemia
a,
e
14 9 2 3 12 2 Enzyme deficiency and elevated galactose-1-phosphate in DBS and
erythrocytes
Others conditions
Maternal
3-MCCD
f
6 6 6 Characteristic acylcarnitine profile in plasma/DBS of mother and clearing
of the pathological profile in the newborn
Not confirmed
d 44 3 1
Total 377 355 11 11 239 82 56
a Legal screening panel in Germany from April 1
st 2005 onward
b Diagnosed by prenatal diagnosis
c Deceased: One child with mTFP at 6 months, one child with NKH in the neonatal period
d Screening diagnoses: 1 CTD lost to follow up; 1 MMA lost to follow up; 1 MCADD, gestational age = 26 wks., deceased in neonatal period; 1 TYR I, gestational
age = 25 wks., deceased in neonatal period
e Disorder with risk of metabolic decompensation
f Disorder without risk of metabolic decompensation
Abbreviations: ASLD = Argininosuccinate lyase deficiency; BIOD = Biotinidase deficiency; CACTD = Carnitine acylcarnitine translocase deficiency; CIT I =
Citrullinaemia type I; CPT ID = Carnitine palmitoyltransferase I deficiency; CPT IID = Carnitine palmitoyltransferase II deficiency; CTD = Carnitine transporter
deficiency; GA I = Glutaric aciduria type I; HCSD = Holocarboxylase synthetase deficiency; HMG-CoA LD = 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency; IVA =
Isovaleric aciduria; KTD = b-Ketothiolase deficiency; LCHADD = Long-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency; mTFP = mitochondrial tri-functional
protein deficiency; MADD = Multiple acyl-CoA dehydrogenase deficiency; MCADD = Medium-chain acyl-CoA dehydrogenase deficiency; MBD = 2-Methylbutyryl-
CoA dehydrogenase deficiency; 3-MCCD = 3-Methylcrotonyl-CoA carboxylase deficiency; MGA = 3-Methylglutaconic aciduria; MHBD = 2-Methyl-3-hydroxybutyryl-
CoA dehydrogenase deficiency; MHP = Mild hyperphenylalaninaemia; MMA/Cbl = Methylmalonic acidurias (all kinds); MSUD = Maple syrup urine disease; NKH =
Non-ketotic hyperglycinaemia; PA = Propionic aciduria; PKU = Phenylketonuria; PTPSD = 6-Pyruvoyltetrahydropterin synthase deficiency; SCADD = Short-chain
acyl-CoA dehydrogenase deficiency; TYR I/III = Tyrosinaemia type I/III; VLCADD = Very long-chain acyl-CoA dehydrogenase deficiency
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NBS or specific metabolic analyses (c
2(2, N = 236) =
38.75; p < 0.001), age at confirmed result (c
2(2, N = 234)
= 25.77; p < 0.001), and age at start of treatment (c
2(2, N
= 230) = 30.11; p < 0.001) with all process times being
later for group 2 than for group 3, but still earlier than
for group 1. Disease specific treatment (in group 1) or
supportive treatment (in group 2) often started before
confirmation of diagnosis. Only in two symptomatic
patients (one medium-chain acyl-CoA dehydrogenase
deficiency, one galactosaemia) NBS was faster than the
results of specific diagnostic investigations (Table 2). In
phenylketonuria immediate start of treatment is not
necessary and would even interfere with confirmatory
testing. Treatment in phenylketonuria patients started
less often before confirmation of diagnosis (27%) than in
disorders at risk for acute metabolic decompensation
(42%) (Fisher’se x a c tt e s tp=0 . 0 3 ) .
Part 2: Outcome analysis
Metabolic decompensations
Disorders were classified according to their risk of
developing decompensation or not (see Table 1). Infor-
mation on metabolic decompensation was available for
133 patients with a potentially decompensating disorder.
At least one metabolic decompensation was reported for
34 (25.6%) patients: 19 out of 113 (16.8%) patients in
group 1 (NBS) (see Table 1) suffered one or more
decompensations, all 11 patients (100%) in group 2
(symptomatic) had altogether 28 decompensations and
four out of nine patients (44%) in group 3 (high risk)
had altogether 17 decompensations. All patients with
classical urea cycle disorders (5/5 patients; four
citrullinaemia type I, one argininosuccinate lyase defi-
ciency) experienced at least one metabolic crisis, fol-
lowed by amino acid disorders (5/10 patients;
decompensations only in maple syrup urine disease),
galactosaemia (6/13 patients), organic acid disorders (8/
20 patients: three isovaleric aciduria, two propionic acid-
uria, one cobalamin C/D defect, one 3-hydroxy-3-
methylglutaryl-CoA lyase deficiency, one glutaric acid-
uria type I), and fatty acid oxidation disorders (10/85
patients: six medium-chain acyl-CoA dehydrogenase
deficiency, three long-chain 3-hydroxy-acyl-CoA dehy-
drogenase deficiency, one very long-chain acyl-CoA
dehydrogenase deficiency). The highest number of
decompensations per individual patient was observed in
patients with classical citrullinaemia (one patient with
six decompensations), propi o n i ca c i d u r i a( o n ep a t i e n t
with seven decompensations) and argininosuccinate
lyase deficiency (one patient with ten decompensations).
Comparison of four groups of disorders (1) mild
citrullinaemia (n = 4) and mild isovaleric aciduria (n =
10), (2) medium-chain acyl-CoA dehydrogenase defi-
ciency (n = 69), (3) fatty acid oxidation disorders other
than medium-chain acyl-CoA dehydrogenase deficiency
(six very long-chain acyl-CoA dehydrogenase deficiency,
four long-chain acyl-CoA dehydrogenase deficiency, two
carnitine transporter deficiency, three multiple acyl-CoA
dehydrogenase deficiency, one carnitine palmitoyltrans-
ferase I deficiency), and (4) urea cycle disorders (five
citrullinaemia type I classic, one argininosuccinate lyase
deficiency), organic acid disorders (six glutaric aciduria
type I, five isovaleric aciduria classic, four propionic
aciduria, four methylmalonic acidurias, one 3-hydroxy-
3-methylglutaryl-CoA lyase deficiency), and amino acid
Table 2 Process times for patients who became symptomatic before first blood sampling or before the first screening
result was available
Diagnosis Age at decom-
pensation
(days)
Age at blood samp-ling
1st screening card (days)
Age at 1
st screening
result (days)
Age at con-firmed
diagnosis (days)
Age at start of
treatment (days)
MCADD 0.0 4.0 11.0 12.0 14.0
MCADD 3 1.7 6.8 6.0 3.0
CIT I classic 1.0 3.0 12.0 2.0 2.0
CIT I classic 1.0 3.0 10.0 5.0 Not available
CIT I classic 2.0 2.7 8.6 2.0 2.0
IVA classic 3.0 4.4 10.7 8.0 8.0
PA 3.0 3.0 16.0 3.0 3.0
Cobalamin C/D
defect
3.0 5.0 15.0 5.0 5.0
Galactosaemia 4.0 3.5 7.0 8.0 7.0
Galactosaemia 8.0 4.2 11.1 9.0 9.0
MSUD 4.0 3.4 9.3 5.0 5.0
Abbreviations see Table 1
Bold text indicates that the first screening result arrived after confirmed diagnosis.
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naemia type I, one 6-pyruvoyltetrahydropterin synthase
deficiency) regarding their patterns of metabolic decom-
pensation revealed a clear cut order of severity (0%, 9%,
25%, 50% decompensations, Figure 1). Kaplan-Meier
analysis Mantel-Cox Log Rank test was significant for
comparison between groups (1) vs. (4) (c
2=9 . 6 ;p=
0.002), (1) vs. (3) (c
2= 4.0; p <0.05), and (4) vs. (2) (c
2=
26.4; p <0.0001), showed trends for (2) vs. (3) (c
2=3 . 0 ;
p = 0.083) and (3) vs. (4) (c
2=3 . 5 ;p=0 . 0 6 1 ) .T h ed i f -
ference between (1) and (2) was not significant (c
2=1 . 3 ;
p = 0.260).
Clinical signs, cognitive outcome and school placement
Standardised clinical status examination investigated 32
clinically relevant signs related to central nervous sys-
tem, peripheral nervous system, muscle, heart, eye, liver,
skin, kidney, haematopoesis and growth. For each disor-
der critical subsets of signs were defined (Additional file
1). Patients with ≥ 1 sign received a positive clinical sta-
tus score. For 75 patients with decompensation disor-
ders and 50 patients with phenylketonuria (total 125) at
least one status evaluation was available. Out of the 75
patients with decompensation disorders, 19 (25.3%)
were scored positive. Table 3 shows the highest rate of
positive clinical status in symptomatically diagnosed
patients (50%), while phenylketonuria and medium-
chain acyl-CoA dehydrogenase deficiency had similarly
low scores. Nine of 48 (18.7%) patients with a decom-
pensation disorder but without decompensation had ≥ 1
sign compared with ten of 27 (37%) patients with at
least one metabolic decompensation (OR: 2.55; 95% CI
[0.88; 7.40]).
Standardised psychological assessment was done in 120
patients at a mean age of 3.3 years (SD = 1.9). Psycho-
metric results were scored as subnormal for IQ results <
85. In the group of 70 patients with a decompensating
disorder, 4 out of 44 (9.1%) without decompensation
had a subnormal outcome compared with 6 out of 26
( 2 3 . 1 % )w i t ha tl e a s to n ed e c o m p e n s a t i o n( O R :3 . 0 0 ;
95% CI [0.76; 11.86]).
School placement is only known for 24 of 28 patients
equal or older than 6 years (the target age for formal
schooling in Germany). All patients with medium-chain
acyl-CoA dehydrogenase deficiency (9/9) or with phe-
nylketonuria (7/7) attend normal schools. For the more
severe disorders 3/8 are not able to attend normal
schools.
In the group of patients with medium-chain acyl-
CoA dehydrogenase deficiency genotype was known
for 28 patients. Of these 16 were homozygous for the
common mutation c.985A >G (K329E). Metabolic
decompensations were observed in 6 patients. In five
of these, the results of neurological status and IQ tests
were normal on follow up. One patient showed normal
intellectual and physical development, but slight myo-
cloni on neurological examination. The only patient in
our cohort with medium-chain acyl-CoA dehydrogen-
ase deficiency who showed severe neurological and
intellectual impairment (IQ 74) never experienced a
metabolic decompensation. However, he presented
with severe neonatal onset cardiomyopathy, which
seems to be part of a syndromatic condition and
unrelated to medium-chain acyl-CoA dehydrogenase
deficiency.
Figure 1 Kaplan-Meier analysis of decompensations in disjunct subsamples of (1) mild isovaleric aciduria and mild citrullinaemia (Mild
IVA, mild CIT), (2) medium-chain acyl-CoA dehydrogenase deficiency (MCADD), (3) other fatty acid oxidation disorders (FAOD), and (4)
urea cycle, organic acid and amino acid disorders (UCD, OA, AA).
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without phenylketonuria as well as biotinindase defi-
ciency versus disorders additionally screened until 2005
showed significant differences for clinical status (OR:
24,3; 95% CI [5.5; 106]), as well as for IQ results (OR:
9.2; 95% CI [2;41]). Comparison of disorders of the
screening panel 2005 without phenylketonuria and bioti-
nidase deficiency versus phenylketonuria alone did not
reveal any significant differences, neither for clinical sta-
tus scores (OR: 0.9; 95% CI [0.3; 2.8]) nor for IQ results
(OR: 1.0; 95% CI [0.3; 4.0]). Standardised clinical status
was significantly associated with psychometric results in
decompensation disorders (C = 0.44; p <0.001) as well
as in phenylketonuria patients (C = 0.46; p <0.01).
Discussion
1,084,195 newborns screened in our centre correspond
to about 1.6 times the annual birth rate in Germany. As
far as we know this is the first prospective single centre
evaluation of a NBS programme utilizing MS/MS.
Numerous publications describe the epidemiology, tech-
nical aspects and clinical validity of MS/MS screening
while there are only a few retrospective evaluations of
NBS programmes. Only the Australian screening pro-
gramme provides data on similar aspects of overall test
performance for groups of disorders as well as of fol-
low-up results [13].
In our cohort 75% of all patients started treatment
within the first 13 days of life. Out of 133 patients at
risk for episodes of decompensation 11 (8%) presented
clinically before the screening result was available. Even
taking blood samples at 24 hrs after birth and optimal
further processing of specimens would not have pre-
vented most of these patients from early adverse events
(Table 2). Kaplan-Meier-analysis revealed disorder
related patterns of early and late decompensations (Fig-
ure 1). Urea cycle disorders, organic acid disorders, and
amino acid disorders show the highest, earliest and con-
tinuous risk. Patients with medium-chain acyl-CoA
dehydrogenase deficiency have a continuous but much
lower risk for episodes of decompensation, and other
fatty acid oxidation disorders an intermediate risk start-
ing towards the end of the first year (with first intercur-
rent illness and/or missing feeds).
In medium-chain acyl-CoA dehydrogenase deficiency
NBS leads to prevention of metabolic decompensations
and neurological harm in nearly all patients [14,15],
compared to 40 to 74% presenting with severe illness,
16-26% with early death and 20% developing severe neu-
rological impairment in unscreened populations [16-18].
This benefit remains relevant although the number of
MCADD cases detected is almost doubled by NBS.
However, contemporary patients from unscreened
cohorts surviving metabolic decompensations also
showed normal neurological outcome, most probably
due to improved awareness and emergency treatment
[13].
Our data correspond well to those of the Australian
study [13] for the common set of disorders as well as
for medium-chain acyl-CoA dehydrogenase deficiency
alone, except for the prevalence of symptomatic cases
presenting during the first days of life (Table 4). One
patient showed normal intellectual and physical develop-
ment, but slight myocloni on neurological examination.
As the patient’s mother showed similar symptoms, these
are most probably unrelated to medium-chain acyl-CoA
dehydrogenase deficiency. In his brother, also with med-
ium-chain acyl-CoA dehydrogenase deficiency, mild
muscular hypotonia without any practical consequences
in everyday life was observed during the standardized
Table 3 Clinical status score and cognitive outcome at the age of 3 yrs, 3 months
Subsample Positive clinical status score*; number
(%)
Cognitive outcome IQ <85; number
(%)
Symptomatic group 3/6 (50) 4/6 (66.7)
High risk group 1/7 (14.3) 3/7 (42.9)
NBS without MCADD and PKU 12/30 (40.0) 2/26 (7.7)
NBS: MCADD 3/32 (9.4) 1/32 (3.1)
NBS: PKU 7/50 (14.0) 4/49 (8.2)
Total 26/125 (20.8) 14/120 (11.7)
Disorders of screening panel 2005 without PKU and BIOD
$
8/61 (13.1) 5/60 (8.3)
Additional disorders screened until 2005
# 11/14 (78.6) 5/11 (45.5)
Abbreviations see Table 1
* ≥ 1 disorder specific clinical sign
$ MSUD, Galactosaemia, MCADD, LCHADD, VLCADD, CPT ID, CPT IID, GA I, IVA
# Cobalamin C/D defect, PA, HMG-CoA LD, CIT I, ASLD, TYR I, CTD, MADD
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Australian study both ratings were judged as “nil signifi-
cant”. In the present study 11 out of 1,084,195 children
presented clinically before the screening result was avail-
able compared to 12 of 461,500 in the Australian
screened cohort (OR: 0.39; 95% CI [0.17; 0.88]). Both
studies document the value of extended newborn
screening mainly on the basis of medium-chain acyl-
CoA dehydrogenase deficiency, a disease of European
origin.
Using phenylketonuria as a gold standard, patients
with metabolic disorders included in the German 2005
screening panel achieved similarly good outcome data,
whereas the outcome of the set of disorders screened
additionally until 2005 was significantly worse than the
outcome of the 2005 screening panel. Not including
these disorders as a group into the screening panel
could be defended as rational, although numbers are too
small to draw conclusions for single disorders.
Evaluation of diseases with much lower frequencies can
benefit from national and international collaboration, as
could be shown for glutaric aciduria type I [19,20], as
well as from comparison with historical controls, well
designed “n-of-1” trials and translational research [21].
Systematic follow-up is also necessary to solve the ques-
tion of mild phenotypes probably representing non-
diseases.
Although unnecessary treatment of mild phenotypes
of metabolic disorders is a serious problem [22], it
seems unjustified to attribute the issue exclusively to
NBS. Considering screening as a programme there are
multiple steps to identify mild variants and revise treat-
ment decisions. Sampling time and cut-offs influence
detection rates of mild variants and the same is true for
methods and cut-offs of confirmatory procedures.
Duarte galactosaemia needs no further investigation and
no reporting [23], but unfortunately this is not yet
known for most other disorders. Therefore evaluation of
the whole process including follow-up is necessary. Ear-
lier sampling may allow earlier detection of some disor-
ders e.g. maple syrup urine disease, but also increases
the risk of missing others e.g. homocystinuria.
The principle that population screening requires a
structured evaluation has been recently set in place by
the US Health and Human Services Secretary’s Advisory
Committee on Heritable Disorders in Newborns and
Children (SACHDNC) instituting a permanent review
panel in 2007 [24]. Five criteria have been defined to
add a condition to the NBS panel: sufficient information
about the condition itself, evidence regarding appropri-
ate screening tests, diagnostic methods, treatment and
economic evaluations. In the European Union an evalua-
tion process was recently initiated with the tender No.
EAHC/2009/Health/09 ‘Evaluation of population new-
born screening practices for rare disorders in Member
States of the European Union’ [25]. Reports on NBS
programmes from different parts of the world are neces-
sary to allow a comprehensive assessment of benefits,
h a r m sa n dc o s t so fN B Sp r o g r a m s[ 2 6 ] .A sp r e v a l e n c e s
are likely to be different in populations of diverse ethni-
cal background, pilot projects in individual countries
will contribute important information [27,28]. In the
Table 4 Comparison of data across studies
Wilcken et al., 2009
[13]
Screened cohort
born 1998-2002
N = 461,500
This study
Screened cohort
born 1999-2009
N = 1,084,195
OR; 95%
CI
Prevalence group 1:MSUD, BIOD, GA I, IVA, MCADD, CACTD, CPT
ID, CPT IID; LCHADD, VLCADD
n=3 7
8.0:100,000
n = 122
11.25: 100,000
1.40;
[0.97;2.02]
Prevalence group 2:Group 1 without MCADD n = 13
2.8: 100,000
n=4 1
3.8: 100,000
1.34;
[0.72;2.51]
MCADD
Prevalence n = 24
5.2: 100,000
n=8 1
7.5: 100,000
1.44;
[0.91;2.27]
Clinical presentation by day 5 N = 2 N = 2
Asymptomatic or clinical presentation after day 5 N = 22 N = 79
Metabolic decompensation during follow-up Not reported 6/69
Physical score nil significant at 6 (Australia)/3 (Heidelberg) years 22/22 31*/32
No intellectual handicap at 6 (Australia)/3 (Heidelberg) years (IQ or intellectual
development in normal range (IQ≥85))
22/22 31*/32
Normal school at ~6 yrs 15/15 9/9
Abbreviations see Table 1
* one patient never showing a metabolic decompensation but congenital cardiomyopathy of unknown origin. The clinical signs of two of three MCADD patients
with a “positive” clinical status score (Table 3) were judged as non significant (see text).
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Page 8 of 10Arabic Gulf country Qatar the overall frequency of
metabolic disorders detected by the particular NBS pro-
gram is much higher (1:966) compared to the present
study (1:2920), and prevalence in a Turkish pilot study
was 1:839 [29] illustrating a presumably likely high ben-
efit of extended NBS in Turkey, Middle East and North
African countries. In contrast the first comprehensive
report from an East Asian country, Taiwan, revealed a
prevalence of 1:6200 for all metabolic disorders, with an
exceedingly low yield of fatty acid oxidation disorders,
one of the main justifications for MS/MS screening in
Caucasian populations [30].
We have presented the data of a single centre longitu-
dinal registry so that they can be compared with others.
Aside from economic evaluation all the criteria set by the
SACHDNC [24] for extended NBS were addressed. We
could demonstrate that physical and cognitive outcome
of patients with presymptomatic diagnosis of metabolic
disorders included in the current German screening
panel is equally good as in patients with phenylketonuria.
However, the specific evaluation of most of the rare dis-
orders is still necessary and will require international
registries and collaborative studies.
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